Sanofi-aventis (Value Right)(GCVRZ)- NASDAQ
  • Sep. 11, 2014, 7:46 AM
    • In an interview with Reuters, Genzyme's (NYSE:SNY) (NASDAQ:GCVRZ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader in the field via new products and acquisitions.
    • He is confident about the commercial success of Lemtrada (alemtuzumab) and Aubagio (teriflunomide). Analysts forecast Lemtrada's peak sales at $437M and Aubagio's at $1.2B.
    • Predictably, no word on acquisition targets, but he says that they are looking to acquire truly innovative products. "If the opportunity is the right opportunity, we'll evaluate it...We're well-resourced to execute our strategy."
    • The firm expects an FDA decision on its revised marketing app for Lemtrada in Q4. The agency rejected its initial application last December.
    | Sep. 11, 2014, 7:46 AM
Company Description
Sanofi is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company also discovers, develops and distributes therapeutic solutions.
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: France